Deep brain stimulation (DBS) has become a well-accepted medical therapy in the treatment of movement disorders such as Parkinson's disease, and is currently under investigation as a treatment for other disorders, including epilepsy. Although DBS is widely used, its therapeutic mechanisms remain poorly understood. Recent research shows that seizures are network-level phenomena, but the incomplete knowledge of neural circuit function has left a gap in our understanding of how disruption at a molecular or cellular level generates epilepsy. In addition, DBS may potentially provide the opportunity to selectively modulate targeted brain regions and related networks. Therefore, a better understanding of the relationship between normal neural networks and epileptogenic networks, as well as the role of DBS in the modulation of neural networks will help us to find the optimal stimulation targets and parameters to achieve a better therapeutic effect. This review will outline the most recent advances in the relationship between normal brain networks and epileptogenic networks, and the modulation of DBS on the excitability of epileptogenic networks. We will then discuss how to optimize DBS stimulation targets and parameters by taking into consideration the concept of network modulation in order to improve treatment of epilepsy in the future.
Introduction
Epilepsy is a common neurological disease, which is estimated to affect approximately 50 million people worldwide, but up to 15 million (30%) patients may experience inadequate control of their seizures with antiepileptic drugs [1] . A further treatment option for the so-called drug-refractory epilepsy is epilepsy surgery, which aims to remove the epileptogenic brain tissue. Many cases can be completely controlled by epilepsy surgery, but not all pharmacoresistant patients are surgical candidates, e.g. when the involved area lies in these functional regions such as the motor cortex or language or visual areas. As for this kind of patients, who are pharmaocrefractary and not eligible for epilepsy surgery, e.g. multiple epileptic foci or of unclear origin, Deep brain stimulation (DBS) is considered as a palliative treatment [2] . DBS involves the intracerebral implantation of stimulation electrodes, which are connected to a subcutaneous pulse generator that continuously delivers electrical pulses. This allows for precise activity modulation of remote brain areas and targeted nuclei [3, 4] . Nowadays, DBS is used as a conventional treatment for Parkinson's disease and other movement and psychiatric disorders [5] .
Applying electrical stimulation to modify brain function is an old concept that has gained much attention since the 1950s [6] . Since the pioneering studies of Cooper et al. on the treatment of epilepsy by cerebellar stimulation in the 1970s [7] , neurologists have tried using DBS to treat refractory epilepsy. Research shows that DBS can terminate or reduce seizures [8] [9] [10] . Recent research shows that seizures are network-level phenomena [11, 12] , but the incomplete knowledge of neural circuit function makes it difficult to understand how disruption at a molecular or cellular level generates epilepsy. Research on the application of DBS for epilepsy has a long history, and a number of different brain targets have been investigated over several decades of study [13] [14] [15] [16] [17] [18] [19] [20] . In general, most of the brain targets used today are based on historical neurosurgical lesion sites, while others are hypothesis derived from the current understanding of brain networks. Moreover, stimulation parameters and patterns employed across indications have also been empirically based upon clinical observations.
Although there is not a clear understanding of the therapeutic mechanisms of action of DBS, it is highly effective in the treatment of many neurological and psychiatric disorders [21] .
There is no doubt that clinical developments in the past did not require a detailed understanding of the neural mechanisms of DBS, but such an understanding may prove useful for us to explore new clinical applications [22] . Therefore, future research on the efficacy of DBS for epilepsy may be enhanced by an improved understanding of the mechanisms involved, especially regarding network modulation by nucleus stimulation. Furthermore, as epilepsy is a heterogeneous network-level condition [12] , a better understanding of the relationship between normal neural networks and epileptogenic networks, as well as the role of DBS in the modulation of epileptogenic networks, will help us find optimal stimulation targets and parameters. This review will outline the most recent advances in the relationship between normal brain networks and epileptogenic networks and the modulation of DBS on the excitability of epileptogenic networks. We will then discuss how to optimize DBS stimulation targets and parameters by taking into consideration the concept of network modulation to improve the treatment of epilepsy in the future.
Literature review method
We searched for articles in PubMed and Google Scholar from January 1973 to January 2017 using the following keywords: (1) 'deep brain stimulation' or 'DBS' and 'epilepsy'; (2) 'network' or 'circuit' and 'epilepsy'. The following criteria were used to make articles included: (1) articles written in English; (2) review articles and (3) original articles.
Normal brain networks and epileptogenic networks
With the development of the emerging field of network science, it has indicated that the brain networks mainly included smallworld topology, highly connected hubs, and hierarchical modularity [23] . Network studies of the brain is emphasized by the range of network alterations, and the results of these researches have been identified in neurological and psychiatric disorders, including depression [24] and Alzheimer's disease [25] . Normal brain networks are known to control normal physiological functions, such as motor function [26, 27] and respiration [28] . It is quite difficult to understand the function of neural networks because there are many uncertainties and complexities in their operations [29] . However, elucidating the function of neural networks is meaningful in advancing our knowledge of normal brain function as well as understanding and treating brain disorders. The brain contains a variety of reciprocal excitatory and inhibitory interconnections both in local circuits and in long range network interactions. These networks are very crucial for normal information processing, but sometimes they may also convey abnormal signals in disorders such as epilepsy. Some studies have suggested that different oscillatory patterns within brain networks may reflect different states of normal function [30] . However, other studies analyzing field potentials recorded from implanted electrodes in human patients with Parkinson's disease and other disorders indicate that these patterns may reflect pathological states associated with specific symptoms of neurological disease [31] .
In recent years, we have witnessed a paradigm shift in the study of epilepsy, which is increasingly understood as a network-level disorder [32] . The concept of epileptogenic networks stems from the idea that there exists seizure-generating 'foci' embedded in a web of structural and functional connections [11] .
For example, the most common refractory epilepsy, temporal lobe epilepsy (TLE), is defined as a focal epilepsy [33] and is pathologically associated with hippocampal sclerosis [34] . The accompanying symptoms of temporal lobe seizures are diverse, such as loss of consciousness, dystonic movements and neuroendocrine changes. Studies by Blumenfeld suggested that complex behavioral manifestations may result from focal abnormal activity in temporal lobe and subcortical neural networks, which is linked to widespread impaired function of the association cortex, separate away from the temporal lobe [35] . However, the relationship between widespread network involvement and impaired consciousness has not been thoroughly investigated.
Likewise, the most common seizure type in refractory epilepsy, focal seizures, are heterogeneous in seizure onset zone and clinical manifestations, and they often propagate along neural pathways. These well-defined networks include the cortical-striatal-thalamic network [36] [37] [38] and the circuit of Papez [39, 40] , which provide nodes for brain stimulation targeted at regulating localized brain areas. Stimulation could be applied directly to a seizure focus or along a conducting pathway to exert its effects. One of the most well studied networks is the circuit of Papez. Initially, the circuit of Papez was characterized for its role in mediating emotions. Subsequent investigations have elucidated its central role in encoding memory and its association with the generation and propagation of epileptic activity [41] . The circuit of Papez links the hippocampus to the thalamus, the cingulate gyrus, and entorhinal cortex/parahippocampal gyrus. Fibers originate from the hippocampus (subiculum)-project, via the fornix, to the mammillary bodies, which in turn links to the hypothalamus and then, via the mammilothalamic tract, to the anterior nucleus of the thalamus (ANT). The ANT communicates with the cingulate gyrus and then links to the parahippocampal gyrus, followed by the entorhinal cortex, which finally projects back to the hippocampus [39, 40] . If seizures propagate along the known circuit, then interrupting the circuit through stimulation of some points along this pathway could potentially prevent the generation and propagation of clinical and subclinical seizures. Over the past decades, electrical stimulation of multiple nodes along these networks, including the hippocampus [42] [43] [44] [45] [46] [47] [48] , mammillary bodies [49] , subiculum [50] , and ANT [51] , has been demonstrated to be effective treatment for epilepsy. A study reported in 2016 has indicated that the efficacy of thalamic stimulation for epilepsy depends on the type of seizure [52] . A recent meta-analysis showed that generalized seizures responded better to vagus nerve stimulation than focal seizures [53] . In the famous SANTE trial study, it has been proved to be effective for focal epilepsy by stimulation of the anterior nucleus [51] , while other studies have showed that for those generalized epilepsies, the centromedian nucleus stimulation appears to be more effective [54] [55] [56] .
Another well-studied circuit is the cortico-thalamo-cortical loop, which appears to be involved in absence seizures [57] . In a nonhuman primate model of chronic focal motor seizures, thalamic lesions restricted to the anterior part of the ventropostero-lateral nucleus were able to produce long-lasting improvement and in most cases led to almost complete seizure suppression [58] . To identify and manipulate neural signal within the thalamo-cortical network, more precisely designed investigation is currently being performed [59] and these networks have implicated multiple potential neuromodulatory targets for the treatment of epilepsy.
Researchers applied cerebellum stimulation to the treatment of epilepsy according to the hypothesis that thalamic fiber tracts are associated with cerebellum [60, 61] . The earliest subcortical target of stimulation for epilepsy was the cerebellum, which was found, in as early as the 1950s, to modify seizures in animal models [62] . The mechanism of action was originally thought to be thalamic inhibition via stimulation-induced Purkinje cell output, but this remains somewhat unclear [48] . Therefore, in future research, to achieve the greatest therapeutic effects and to identify the optimum targets and parameters for DBS, it requires a greater understanding of epileptogenic networks and the underlying mechanisms of the effects of electrical stimulation.
Modulation of epileptogenic network during DBS
In past decades, both precise stereotactic techniques and rigorous trial design combined to make DBS a viable treatment option. Nonetheless, the mechanisms of action of these stimulatory treatments are poorly understood. Over the past several years, different aspects of the mechanisms of DBS have been revealed by different investigations, which may vary depending on the kinds of disease, the stimulation targets and also the animal models used. Though several mechanisms of action of DBS have been proposed, a detailed mechanism has yet to be established, and study has suggested that stimulation of brain structures with electrodes may inhibit those structures [2] . In addition to affecting the stimulated structures, DBS also influences the neural networks with widespread influences as revealed by electrophysiological and neurochemical studies.
Electrophysiological research to explore the mechanisms of action of DBS
A number of experiments that explored the mechanisms underlying DBS are based upon electrophysiological studies in animal models or microelectrode recordings in patients during DBS surgeries. Stimulation of deep brain structures produces profound effects on remote brain areas through neural networks and connections. These effects of DBS on brain activity have also been investigated with non-invasive techniques such as electroencephalography (EEG) and magneto-encephalography (MEG) [63] .
Many animal studies have confirmed that the anterior nucleus of the thalamus (ANT) is an important node in the circuit of Papez, which can influence the initiation and propagation of seizures [64] [65] [66] [67] . Electrophysiological mapping of the circuit has also been conducted in patients with intractable epilepsy undergoing DBS of ANT. Both localized EEG activity recorded in the temporal region [68, 69] and evoked potentials recorded with depth electrodes in the hippocampus (HC) in response to ANT stimulation [70, 71] have confirmed that there is a strong connection between these structures in humans, and indicated that it is possible to modulate brain network activity with ANT stimulation [72] . The distinct suppression of hippocampal activity by brain stimulation indicates a potential therapeutic mechanism of DBS for epilepsy that is consistent with current theories of DBS network effects.
To further study evoked potentials from DBS, several studies have used EEG to investigate the effects of different patterns of stimulation on the evoked response, including single-, pairedpulse, and burst stimulation. In general, the results of these studies have shown that DBS can produce a series of cortical evoked potentials starting at a latency of 1-3 ms [73] [74] [75] . Moreover, somatosensory evoked potentials (SEP) recorded from contacts of DBS electrodes and microelectrodes in the thalamus and the subthalamic nucleus (STN) are used to determine the position of electrode contacts in relation to sensory pathways [76] . The onset times of the potentials were similar in the cortex, STN, and ventral lateral nucleus (VL), ranging from 1.5 to 2 ms before electromyogram onset [77] . In 2002, Dinner et al. recorded EEG and evoked potential from the STN for DBS of intractable epilepsy in patients, and the results showed that interictal sharp waves recorded in the scalp EEG were always negative in polarity, which were always associated with sharp waves recorded at the ipsilateral STN electrode contacts that were always positive in polarity [78] . The study demonstrated that the STN activity was most probably an expression of the direct cortico-STN glutamatergic pathways, which may be important with regard to a possible mechanism for the treatment of epilepsy with STN stimulation.
Above all, electrophysiological modality such as EEG provides a direct understanding of the effects of DBS for epilepsy on the epileptogenic networks. Although brain networks are spatially extended in both a local and global sense, and some information about local or regional activity can be obtained from EEG, much electrophysiological information can be acquired about neural networks during DBS in future studies with the advent of large scale simultaneous microelectrode recordings systems.
Neurochemical mechanism of DBS for epilepsy
Over the past centuries, the treatment of epilepsy has been guided by preconceptions regarding its origin [79] . Various excitatory and inhibitory neurotransmitters, such as glutamate (Glu) and GABA, were believed to play an important role in the initiation, spread and maintenance of epileptic activity [80] . Recent findings on pathogenesis of epileptic seizures indicated that the imbalance between the excitatory and inhibitory neurotransmitters may result in seizures [81, 82] .
It is widely accepted that the gold standard for neurochemical measures is microdialysis, which have been used to measure multiple neurotransmitters [83] [84] [85] . As Glu is the main excitatory neurotransmitter in the brain, many studies have been performed both in anesthetized and awake animal models [86, 87] to try to explore the underlying mechanism of epilepsy. However, research has shown that this technique is limited in its spatial and temporal recording capabilities, and it may produce damage remote from the implant site, has slow response times, may alter brain metabolism, and produce an astrocytic barrier following chronic implantation [88, 89] . Recently, in vivo amperometric recordings combined with enzyme-based multisite ceramic microelectrode arrays (MEAs) have been used to investigate rapid changes in extracellular levels of glutamate in the brains of anesthetized rats [90] . This newly developed technique has several advantages over other commonly used in vivo methods. Preliminary studies have supported that the recording technique is minimally invasive [91] , it has at least 2 Hz temporal resolution, has the capability to chronically record a variety of neurotransmitters with low levels of detection, and it can record resting neurotransmitter levels using self referencing methods [90] [91] [92] .
Both of the two methods have been used over the past few years. In the early 1990s, a study using bilateral intrahippocampal microdialysis was aiming to test whether an increase in extracellular excitatory neurotransmitter glutamate (Glu) could trigger spontaneous seizures. Their results showed that concentrations of Glu were higher in the epileptogenic hippocampus before seizures, whereas GABA concentrations were lower. In addition, there was a sustained increase in extracellular Glu in the epileptogenic hippocampus during seizures [93] . Stephens et al. applied MEAs technology to measure in vivo extracellular tonic glutamate levels and real-time glutamate release and clearance events in the hippocampus of awake rats, which were locally applied 4-aminopyridine (4-AP) into the CA1 region to induce focal motor seizures. Their results indicated that rats with the highest pre-seizure tonic glutamate levels experienced the greatest degree of acute seizure-associated disruption of glutamate neurotransmission measured as rapid transient changes in extracellular glutamate levels [94] .
To explore the underlying mechanism of DBS for epilepsy, Shi et al. investigated the changes in the neurotransmitters in response to chronic ANT-stimulation in monkeys [95] . When regarding the mechanism of DBS for epilepsy, favorable modulation in amino acid levels to recreate balance is a desirable effect of chronic ANTstimulation. However, whether the alterations in the amino acid levels are a direct result of ANT-stimulation or are related to an ANT-stimulated reduction in seizure activity remains to be determined. Previous studies have shown that high frequency stimulation (HFS) in the rat caudate putamen led to a significant increase of GABA outflow from the ipsilateral nucleus accumbens whereas GABA levels remained unchanged in the control group without HFS. In contrast to GABA, levels of glutamate, 5-HT, dopamine and their metabolites were unaffected by HFS [96] . Another investigation suggested that both glutamate and dopamine are affected by DBS [63] . Thus, the modulation of neurotransmitters following DBS is complex and may also involve interactions with other neurotransmitters within the networks.
Electrophysiological and neurotransmitter modulation likely explains the acute effects whereas plasticity and neurogenesis in hotly debated may explain the chronic effects [97] . The mechanisms of DBS for epilepsy may be more complicated and may involve comprehensive circuit interactions.
Different brain targets: local and remote modulation of network excitability
It has been demonstrated that DBS could reduce seizures in patients with medically refractory epilepsy [98] [99] [100] , and a number of different brain targets, such as thalamus anterior nucleus (ANT), [101] [102] [103] centromedian nucleus [104, 105] , subthalamic nucleus (STN) [101, 106, 107] , and cerebellum [108] [109] [110] have been investigated over the several decades of study. We summary the results for some studies that included relatively larger number of patients and list the results in Table 1 [2, [111] [112] [113] [114] [115] .
According to the recently study by Stypulkowski and his colleagues, the targets used for epilepsy fall into two categories, which represent the two different therapeutic strategies: (1) focal stimulation, with the goal of directly, or through local circuits, affecting the seizure onset zone; and (2) remote stimulation, where the targeted nodes are within larger thalamo-cortical-basal ganglia networks, intended to influence seizure initiation and propagation within these pathways [116] . Early studies viewed brain areas as independent processors within a modular paradigm, but it is now accepted that dynamic functional connectivity among these distributed neural nodes may be the underlying mechanism of many complex neural functions [117, 118] . The most distinct feature of functional networks for local brain connection is the strong interactions between different brain areas [119] . Many studies have been made conducted on the circuit of Papez, a limbic network as described above, which may be related to the generation and propagation of seizure activity [120] [121] [122] . Specifically, Stypulkowski and his colleagues compared the effects of local (hippocampal) and remote (ANT) stimulation on hippocampal activity, as demonstrated by changes in local field potentials (LFPs), and the relationship of these changes to network excitability [116] .
Nowadays, DBS is rather successful for Parkinson's disease, because (a) models of Parkinson disease are clear and (b) the structure stimulated is very small (5 mm structure as the subthalamic nucleus) and can precisely be targeted (1 mm electrode). However, the localisation of an epileptic focus is much more imprecise, even when using a multimodal approach [123] . Therefore, the placement of electrode is much more critical. During the stereotactic electroencephalography (SEEG) recording we know that electrodes can miss to record epileptic discharge when they are misplaced for several millimeters only. The focus localization in epileptology is still only approximate. But there are still some patients could not be well defined of the epileptic focus, therefore are not eligible for epilepsy surgery. But, by taking into account the concept of epileptogenic networks, which stems from the idea that there exists seizure-generating 'foci' embedded in a web of structural and functional connections [11] , DBS may produce profound effects on remote brain areas through neural networks and connections by stimulating of some node along the whole epileptogenic networks. Therefore, this allows for brain stimulation being used remotely in order to modulate the epileptic network.
DBS is a treatment option for epilepsy. On the other hand, it is a complication-prone operation. Complications of DBS were classified into 3 main aspects: (1) operation-related, (2) hardwarerelated and (3) stimulation related [124] . Operation-related complications included electrode malposition and intracranial haemorrhages. The most common complications of DBS mainly comes from the surgical implantation. A recently study [125] described a complication which has not been described previously called 'post op intra-cranial air', which may be a newly possible complication of DBS insertion. Hardware-related complications included infection and erosion, electrode migration and fracture of electrodes. However, stimulation-related complications, such as electrode misplacement, may cause some undesired effects, e.g. paresthesia, emotion impairment and cognitive disorder, and these are usually reversible as reported [51, 103] . The most severe operation-related complication of DBS may be the newly defined "sudden unexpected death in epilepsy" (SUDEP), which is deadly during DBS for epilepsy. It is more common among refractory epilepsy, including those evaluated for epilepsy surgery or those continuing to have seizures after surgery [126, 127] .
Accepting epilepsy as a network-level disorder may be a better way to explain why application of DBS to some nodes of the epileptogenic network can disrupt the underlying pathological network dynamics and provide therapeutic effects. But, why are some stimulation locations better than others? The goal of applying DBS should be to maximize stimulation of the target brain areas with minimal activation of the non-target region, using the least amount of energy possible. Studies hypothesized that the targets for the treatment of epilepsy are those directly connected to epileptogenic networks. Plus, the anatomical structure of the networks provides specific brain regions where multiple circuits converge in a focused area, and one such area is the target region. Therefore, it is not surprising that a well-placed electrode in the target region can generate excellent clinical outcomes with the lowest stimulation power requirements. Altogether, with the conception that DBS for epilepsy by different brain targets is a theory about local and remote modulation of network excitability, it is important to explore more potential neuromodulatory targets among the networks for the treatment of epileptic seizures.
Future directions
Considering the network effects of DBS, further studies should focus on the use of closed-loop, feedback-controlled neurostimulation devices [128] , which can activate electrical stimulation of the previously defined seizure onset zone upon detection of electrophysiological signatures of a seizure, like the so-called RNS With the development of neurostimulation technique, the socalled responsive neurostimulation, RNS 1 System (NeuroPace, Mountain View, CA) [99] has been proposed. It aims to interfere with the accumulation of seizure activity as early as possible to abort or even prevent an upcoming seizure [129] . Electrodes are chronically implanted near the seizure focus to detect epileptic activity and the site of the electrodes is determined in each patient individually. Once epileptic activity was detected, a small electrical stimulation would be delivered to interrupt this activity, which may be developing into a full seizure (closed-loop stimulation). In 2013, RNS 1 was approved in the United States. The FDA approval was based on a randomized double-blinded trial, which showed a 37.9% reduction in seizures [130] . The device is well tolerated and has no emotional or cognitive effects and therefore can help tremendously improve the quality of life in epilepsy patients. Vagus nerve stimulation (VNS) was approved for epilepsy by the FDA in 1997, and it also got the FDA clearance for treatmentresistant depression in 2005 [131] . Current development of responsive neurostimulation in epilepsy is still limited, but seems promising.
Because of the inimitably connection of the anterior nucleus of thalamus (ANT) to the limbic system, good effects were gained in temporal lobe seizures patients, and after the famous SANTE-trial in 2010 [15] , DBS-ANT has been getten Ce marking and approved in Australia, Canada, etc. for clinical treatment of patients with refractory epilepsy, but it has not yet been approved by the US FDA.
A retrospective study with 44 patients [132] and a study using chronic bilateral subthalamic nucleus (STN) stimulation with 12 patients [133] showed that patients who undergo frequent parameter settings adjustments in DBS experience greater clinical improvement compared to those without proper adjustment of DBS parameters. However, designing such a system requires valid feedback control signals.
In comparison with open-loop deep brain stimulation and traditional static control schemes, the newly developed closed-loop control strategy can optimize the stimulation parameters without requiring any particular knowledge of the physiological properties of the system [128] . On that basis, an input-output model can be established to review the relationship between external stimulation and internal responses, and future research will lead to development of new devices that can reliably accept feedback signals to identify the state of the patient and deliver the pattern of stimuli required to modulate pathological neuronal circuits to bring better symptomatic benefits.
A recently important development of DBS is a DBS lead containing directionally-segmented electrodes (dDBS), namely the directionally stimulating electrodes, and by this kind of electrode, stimulation can be oriented toward the structure of interest. It allow for clinicians to more effectively adapt current through and around structures-stimulated in order to achieve a more consistent therapeutic effect without inducing side effects. During 2011-2012, the theoretical analyses have been conducted [134, 135] , and up to 2014, after a double blind, randomized study in Parkinson's disease patients [136] , the device has got CE marked in 2015. The future studies can be conducted to investigate its efficacy in epilepsy patients.
Another newly development in neurostimulation is the interleaving stimulation mode (Medtronic 1 ). Conventional settings, programmed with monopolar, double monopolar or bipolar, may sometimes bring suboptimal outcomes, so interleaved pulses can be used to provide some therapeutic benefits with the possibility of fewer side effects by alternate, automatically [137, 138] . It may be a good tool to increase clinical results, and possibly avoid surgical revisions.
Conclusions
Brain stimulation allows for adjustable and reversible modulation of neurologic disease, including epilepsy. As the underlying therapeutic mechanisms of DBS are poorly understood, a large number of studies have been conducted to try to uncover its basic mechanisms in both human patients and animal models. Animal studies have mainly assisted in the identification of potential targets and parameters, but many clinical studies are only loosely based on fundamental principles derived from the laboratory [12] , and the mechanisms by which DBS reduces seizures remain unclear.
Moreover, as epilepsy is a widespread neurological disorder with a significant morbidity and mortality, and the only available drug therapy is targeting its symptoms rather than the underlying cause, additional studies focused on elucidating the mechanisms of epileptogenesis are needed to explore more specific targets for treatment, with the hope of preventing epilepsy before seizures begin [139] . However, our limited understanding of the mechanisms of DBS action [140, 141] , the epileptogenic networks themselves and their interaction, as well as the nonselective effects of DBS, combine to make this promising therapy still relatively unrefined and dependent on careful empirical progress.
The history of DBS for epilepsy has been heterogeneous with various brain targets, stimulation parameters, and clinical effects. This review here highlights the network effect of DBS in previous investigations, attempting to propose a new way of considering the therapeutic mechanisms of DBS for epilepsy. The general lack of mechanistic understanding of DBS is at least in part due to the inherently nonselective nature of electrical stimulation as a neuromodulatory tool. Specifically, DBS is likely to cause circuit changes both locally and over long distances from the stimulating area, both of which have been shown to confer therapeutic effects.
Experimental research in animal models is and will be of great value in understanding neurobiological mechanisms of DBS 21 and they will provide insight into molecular, electrophysiological, and behavioral aspects of the underlying disorders as well as the mechanism of action of DBS. Ultimately, validation of any mechanism of DBS will require clinical trials with human subjects.
Although genetically based circuit manipulations are not currently possible in humans, recent developments in noninvasive functional connectivity analysis, the so-called resting-state connectivity profile, may provide powerful network-level information about DBS [142] [143] [144] .
Conflicts of interest statement
The authors declare that there are no conflicts of interest.
